TITLE:
Serological Investigation of COVID-19 Antibodies in Armenia
AUTHORS:
Inessa Nazaryan, Shahane Mnatsakanyan, Narek Pepanyan
KEYWORDS:
Coronavirus, IgG, Immunity, Seroprevalence
JOURNAL NAME:
Advances in Infectious Diseases,
Vol.12 No.2,
June
22,
2022
ABSTRACT: Background: In December 2019 in Wuhan China the new coronavirus outbreak emerged and quickly spread in all parts of the world resulting to more than 500,000,000 infection cases and around 6,200,000 deaths. The global incidence of the infection is still growing as well as number of deaths. COVID-19 is a new virus, therefore not much is known about the immune response of infected organism, which is crucial not only for vaccination policy development, but also for identification of public health strategies. Aim: Current research aims to describe COVID-19 IgG levels depending on symptoms, antibiotic and antiviral medications intake history, existing chronic condition and smoking status during March-December of 2020 in Armenia. Furthermore, the study aims to help elucidate the fraction of asymptomatic or presymptomatic/sub- clinical infections in the population and understand the main risk factors for infection complication. Methodology: The cross-sectional study with convenience sampling of individuals who turned to “EcoSense” laboratories to be tested for COVID-19 IgG were examined. The NovaTec SARS-CoC-2 (COVID-19) IgG COVG940 96 Determinations ELISA test kits were used. The questionnaire was filled regarding the COVID-19 status, symptoms, exposure history, disease history, pre-existing chronic conditions, medication and vaccination history. The descriptive as well as multivariate analysis was performed. Results: Overall 1573 testing was performed 837 of subjects agreed to participate in the interview. 24.1% of participants had laboratory confirmed COVID-19 but by the time of interview were already recovered. 212 (25.3%) participants had positive IgG levels, among 126 (15.1%) participants IgG levels were in the grey zone. Out of PCR confirmed cases only 58.7% had positive IgG levels and 3.9% IgG level was in the grey zone. Headache was the most common symptom among participants (37.2% among all participants and 53.1% among participants who previously had positive COVID-19 PCR test). The second most common symptom was anosmia (23.7% among all participants and 48.9% among participants who previously had positive COVID-19 PCR test). 5.4% of participants mentioned previous hospitalization due to COVID-19, 71 (8.5%) mentioned being diagnosed with pneumonia and 24 (2.9%) participants mentioned being admitted to ICU, 20 (2.4%) mentioned receiving oxygen therapy and 4 (0.5%) of the participants mentioned receiving an artificial ventilation of lungs. There was a weak correlation between symptom sum score and IgG titers. The Correlation coefficient was 0.273, p 2 = 0.075. The linear regression analysis was also performed. The obtained results indicate that the number of symptoms patients have is a significant predictor for IgG level F(1, 711) = 57.45, P 2 = 0.075. Conclusions: Our study reviled that around half of PCR confirmed COVID-19 patients do not have positive titer for IgG, most importantly the number of symptoms is a weak predictor for IgG levels, which contradicts the existing misassumption regarding severity of clinical manifestation of COVID-19 and post-infection immunity.